SWOG clinical trial number
C9687
The Role of Salvage Prostatectomy for Radiation Failure in Prostate Cancer.
Closed
Phase
Research committees
Genitourinary Cancer
Eligibility Criteria Expand/Collapse
Pts must have biopsy proven persistence or recurrence of prostate cancer with no evidence of metastatic disease at the time of biopsy. Pts must have a PS of 0-1. Pts must have been treated with >/= 60 cGy external beam RT or brachytherapy for clinical states T1-2, NX, M0 PC w/PSA < / = to 30 ng/ml prior to RT. It must be > / = 18 mos since last RT and > / = to 3 mos since last adj hormonal tx. Pts dx'ed w/another malignancy w/in previous 5 years (except for non-melanoma skin ca or Ta bladder ca) are not eligible. Pts must have a PSA of < / = 20 ng/ml obtained within 30 days prior to registration.
Other Clinical Trials
SWOG Clinical Trial Number
S2419
Phase II/III Double Blinded Trial of Immune-Based Therapy with a Live Biotherapeutic MO-03, or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma (BioFront Trial)
Research Committee(s)
Genitourinary Cancer
Activated
04/22/2026
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
S2427
Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy after a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer (BRIGHT)
Research Committee(s)
Genitourinary Cancer
Activated
09/04/2025
Accrual
10%
Open
Phase
SWOG Clinical Trial Number
CCTG-PR26
A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
Research Committee(s)
Genitourinary Cancer
Activated
01/30/2025
Open
Phase